Boehringer Taps Gubra For Early-Stage Obesity Deal
Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.
You may also be interested in...
Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.
Merck adds to its immuno-oncology R&D heft with purchase of Rigontec, while Allergan will collaborate with Lyndra to produce once-weekly drugs for Alzheimer’s disease.
Leading the pack with partner Lilly in the expansion of diabetes medication into cardiovascular protection, Boehringer Ingelheim looks set to build this year on its healthy 2016 growth. The completion of its acquisition of Sanofi's Mérial animal health business in January will also boost future sales.